EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer

Jan Hrudka, Jan Hojný, Eva Krkavcová, Jiří Dvořák, Zuzana Prouzová, Michaela Kendall Bártů, Nicolette Zavillová, David Čapka, Radoslav Matěj iD, Petr Waldauf

Pathology International · 2026-06 · 76 (6)

DOI: 10.1111/pin.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology International, online erschienen am 16.06.2026. Verfasst von Jan Hrudka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. Hauptthemen laut MEDLINE: Penile Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Squamous Cell, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Karlova v Praze, Ministerstvo Zdravotnictví Ceské Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Penile squamous cell carcinoma (pSCC) is a rare cancer associated with a relatively poor prognosis. The WHO classifies pSCC into HPV‐associated and HPV‐independent subtypes, with HPV‐positive pSCCs showing slightly better outcomes. A key negative prognostic marker is TP53 mutation. The aim of this study was to evaluate the concordance of (1) p16 immunohistochemistry with HPV status determined by PCR, (2) p53 immunohistochemistry with TP53 mutational status obtained by NGS, and (3) prognostic impact of overexpression and null phenotype p53 immunohistochemistry profiles. Analyzing invasive pSCC from 209 patients, we assessed concordance between p16 immunohistochemistry and HPV status ( n = 132) determined by quantitative PCR, obtaining Cohen's kappa Κ = 0.62 ( p < 0.0001). For p53 immunohistochemistry versus TP53 status by NGS ( n = 145), Cohen's kappa reached Κ = 0.693 ( p < 0.0001). We found worse overall survival (Hazard ratio = 3.33, 95% CIs 1.92–5.56, p < 0.0001) in p53 mutated cases ( n = 38, both overexpression and null phenotype) compared to wild type ( n = 171), but without a significant difference between both mutated profiles. Both HPV status and p53 profile can be reliably assessed by immunohistochemistry with substantial agreement. Patients with a mutated p53 profile showed significantly worse survival, irrespective of the mutated profile variant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Penile NeoplasmsTumor Suppressor Protein p53Carcinoma, Squamous CellBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16HumansImmunohistochemistryMalePrognosisPapillomavirus InfectionsMiddle AgedAgedHuman Papillomavirus VirusesMutationAged, 80 and overAdult

Stichwörter der Autor:innen

Human papillomavirus (HPV)ImmunohistochemistryNext generation sequencing (NGS)Penile squamous cell carcinoma (pSCC)Prognostic biomarkersTP53 mutationquantitative PCR (qPCR)

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorCyclin-Dependent Kinase Inhibitor p16TP53 protein, humanCDKN2A protein, human

Autor:innen und Institutionen

  • Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Department of Pathology, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
  • Department of Urology, 3rd Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic.
  • Department of Urology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic.
  • Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic.

ORCID-Profile: Radoslav Matěj

Förderung

  • Univerzita Karlova v Praze
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Hrudka, J., Hojný, J., Krkavcová, E., Dvořák, J., Prouzová, Z., Bártů, M. K., Zavillová, N., Čapka, D., Matěj, R., & Waldauf, P. (2026). Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer. Pathology International, 76(6). https://doi.org/10.1111/pin.70138

Vancouver

Hrudka J, Hojný J, Krkavcová E, Dvořák J, Prouzová Z, Bártů MK, et al. Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer. Pathology International. 2026;76(6). doi:10.1111/pin.70138

BibTeX
@article{Hrudka2026,
  author = {Hrudka, Jan and Hojný, Jan and Krkavcová, Eva and Dvořák, Jiří and Prouzová, Zuzana and Bártů, Michaela Kendall and Zavillová, Nicolette and Čapka, David and Matěj, Radoslav and Waldauf, Petr},
  title = {Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer},
  journal = {Pathology International},
  year = {2026},
  volume = {76},
  number = {6},
  doi = {10.1111/pin.70138}
}
Kostenlos starten →